Many experts are frustrated and troubled by the state of HER2 testing, especially as new opportunities for tests are on the horizon. And as trials testing Herceptin at earlier stages and in ...

The US Food and Drug Administration (FDA) has approved a label expansion for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, into biliary tract cancer (BTC).

The results of the baseline economic analysis by test strategy were as follows ... The results are not sensitive to varying levels of HER2 overexpression in the population, as shown for a US$ ...

SystImmune and Bristol Myers Squibb are testing a bispecific EGFR × HER3 ADC called BL-B01D1/BMS-986507 for various solid tumours. At all ranks who focus on research in Artificial Intelligence ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

Incredible” results from the PATINA trial suggested a new standard of care for HER2, ER-positive metastatic breast cancer.

Our QA program includes tumor analysis, nuclear score, tumor histological grade, IHC score and FISH score. Correlation with IHC and tumor histopathology and performing metrics is mandatory in order to ...

The availability of a simple immunohistochemical (IHC) test for HER2-low status is seen as critical to the successful rollout of Enhertu (trastuzumab deruxtecan) in this category of breast cancer ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The HER2-low and HER2-ultralow breast cancer subtype ...

The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Lynparza (olaparib) for ...